Form 4: Spero Therapeutics Director Kathleen Tregoning Granted 20,000 Restricted Stock Units

Spero Therapeutics, Inc. Director Kathleen Tregoning was granted 20,000 restricted stock units (RSUs) on June 12, 2025, which are set to vest on June 12, 2026.

Summary

• Kathleen Tregoning, a Director of Spero Therapeutics, Inc. (SPRO), acquired 20,000 shares of common stock on June 12, 2025.
• These shares were granted as restricted stock units (RSUs) at a price of $0 per share.
• Each RSU represents the right to receive one share of common stock upon vesting.
• The RSUs are scheduled to vest on June 12, 2026, contingent upon Ms. Tregoning's continued service to the company.
• Following this transaction, Ms. Tregoning beneficially owns a total of 75,000 shares of Spero Therapeutics common stock.

Sentiment

Score: 7

Explanation: The grant of RSUs to a director is a positive signal of alignment between management and shareholder interests, promoting long-term commitment. It's a standard compensation practice, so not exceptionally positive, but certainly not negative.

Positives

• The grant of 20,000 restricted stock units to Director Kathleen Tregoning aligns her interests with those of shareholders, as the value of the RSUs is tied to the company's stock performance.
• The vesting schedule, contingent on continued service, promotes long-term commitment from a key board member.

Negatives

• The issuance of new restricted stock units, upon vesting, will result in a minor dilution of existing shareholder equity.

Future Outlook

The future outlook indicates that the 20,000 restricted stock units granted to Director Kathleen Tregoning are expected to vest on June 12, 2026, provided she continues her service to Spero Therapeutics, Inc.

Industry Context

This transaction is a standard form of equity compensation for directors in the biotechnology and pharmaceutical industry, designed to align executive and board member incentives with long-term company performance and shareholder value.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) to directors is a common practice across publicly traded companies, particularly in the biotech sector, as a non-cash compensation method that ties director incentives to stock performance.
• The vesting schedule, typically over one to three years, is standard for RSU grants to ensure retention and long-term commitment, comparable to practices at companies like Moderna (MRNA) or BioNTech (BNTX) for their non-executive directors.
• The $0 price for RSUs is typical, as they represent a right to receive shares upon vesting, rather than a purchase.

Related Party Transactions

• The grant of 20,000 restricted stock units to Kathleen Tregoning, a Director of Spero Therapeutics, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to better long-term performance. However, it also represents a minor future dilution upon vesting.

Next Steps

• The 20,000 restricted stock units are scheduled to vest on June 12, 2026.

Key Dates

Recommendation

Keywords

Spero Therapeutics, SPRO, Form 4, SEC filing, Restricted Stock Units, RSU grant, Director compensation, Insider transaction, Kathleen Tregoning, Equity compensation